KEY DETAILS
The FDA's crackdown on compounded semaglutide and tirzepatide could make cheaper, pharmacy-made versions of these drugs harder to find.
The FDA has approved Eli Lilly's once-weekly insulin injection for type 2 diabetes, offering an alternative to daily insulin shots.
A new study found that stopping GLP-1 drugs may raise the risk of heart attack and stroke, a factor worth discussing with your doctor.
Eli Lilly's stock rose following recent news, reflecting investor confidence tied to its expanding GLP-1 and insulin product lineup.
A radio interview with Dr. Caridi covers how Ozempic and similar drugs are changing conversations around plastic surgery and aging in Austin.
The FDA is tightening its rules on compounded semaglutide and tirzepatide, a shift that could push many patients back toward brand-name prices. The same day, the agency cleared Eli Lilly's once-weekly insulin injection for type 2 diabetes, giving Lilly another product on the market alongside its GLP-1 drugs. A new study also found that stopping GLP-1 drugs may raise the risk of heart attack and stroke, worth discussing with your doctor. Together, these developments affect what patients can access and what happens when they stop treatment.
The FDA's crackdown targets compounded versions of semaglutide and tirzepatide, the two drugs behind Ozempic, Wegovy, Mounjaro, and Zepbound. Compounding pharmacies have filled a real gap for patients who could not afford the brand-name products or found them out of stock, often charging a fraction of the list price. As the agency tightens enforcement, that cheaper supply may shrink, and patients who have relied on compounded versions could find themselves searching for other options or paying more. If you currently use a compounded GLP-1 drug, it may be wise to ask your pharmacy or prescriber now about how this change could affect your refills.
That same agency also handed Eli Lilly some good news this week, approving its once-weekly insulin injection for type 2 diabetes. For patients who currently inject insulin daily, a weekly option could mean fewer shots and simpler routines, though it will be up to each patient and their doctor to decide if the switch makes sense. The approval adds another product to Lilly's expanding lineup, which already includes its GLP-1 drugs Mounjaro and Zepbound. It is a reminder that the same regulatory body shaping access to compounded drugs is also clearing new brand-name options onto the market.
A separate study raises a different kind of question for anyone on a GLP-1 drug: what happens if you stop. Researchers found that discontinuing these medications may raise the risk of heart attack and stroke, a finding that adds weight to the decision of when and how to come off treatment. This does not mean every patient who stops will face these risks, but it does suggest the choice should not be made lightly or without medical guidance. If you are considering pausing or ending a GLP-1 drug for any reason, this is worth raising directly with your doctor so you can weigh the cardiac risk against whatever is driving the decision to stop.
Investors seem to like what they are seeing from Lilly. The company's stock rose following the insulin approval and the broader run of news around its GLP-1 products, a sign that investors view its expanding lineup as a strong position heading into next year. For patients, stock performance does not change day-to-day treatment, but it does reflect how central these drugs have become to Lilly's business and how much investment the company is likely to keep putting into this category.
Away from the regulatory and financial news, a radio interview with Dr. Caridi took a more personal look at how these drugs are changing conversations in Austin. The conversation covered plastic surgery and aging, along with the ways Ozempic and similar drugs are shifting what patients ask for and expect from cosmetic procedures. It is a reminder that the effects of these medications reach beyond prescriptions and clinical studies, into how people think about their bodies and aging more broadly. For readers curious about that cultural side of the story, the interview offers a candid, local perspective.
Across all of this, the main takeaway for patients is to stay informed and stay in touch with your doctor. If you rely on a compounded GLP-1 drug, check on your supply now rather than waiting for a shortage. And if you are weighing whether to stop treatment, talk through the cardiac risk with your doctor before making that decision. The business and cultural news around these drugs will keep evolving, but your own treatment decisions are the ones worth prioritizing this week.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.